Skip to main content
Photo header of senior man
Senior woman header
Senior woman header

DIAGNOSTIC INSIGHTS FOR LIFE®

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More
Senior man header
Senior woman header
Senior woman header

DIAGNOSTIC INSIGHTS FOR LIFE

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More

Syn-One Test named a top 2024 medical innovation by NIH. 50,000+ patients tested with Syn-One – and counting.

Introducing the Syn-One Test® from CND Life Sciences

The first commercially available skin-based test to help clinicians diagnose Parkinson’s disease and related disorders.

seal icon

CLIA-Certified and CAP-Accredited Pathology Lab

test tube icon

Dedication to Science, Research, Quality, and Reliability

DNA icon

Patient-Focused Mission

microscope icon

High Accuracy: >95% Sensitivity and Specificity

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

CND Insights

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
December 9, 2025

CND Life Sciences Opens Boston Office to Support its Scientific Strategy and Patient-Driven Mission

CND Life Sciences recently added a Boston-area office to support the company’s growth and accelerate…
Insights
December 2, 2025

Highlights of CND Life Sciences Research Presented at MDS

The International Congress of Parkinson’s Disease and Movement Disorders® held this past October in Hawaii…
Insights
November 25, 2025

Studies in Clinical Utility of Skin Biopsy-Based Testing in Synucleinopathies

Prominent Academic Centers Present Findings at the 2025 MDS Congress CND Editorial
VIEW ALL INSIGHTS

News

Check out press releases, news alerts and coverage of CND happenings.

On Our Radar
December 31, 2025

Prevention is the Future of Neurology

As 2025 draws to a close, it’s worth spotlighting the compelling call-to-action from “Prevention Isn’t…
News Release
November 11, 2025

CND Life Sciences’ Syn-One® Biomarker Services Used for Novel Parkinson’s Disease Endpoint in Phase 2 Drug Trial

SCOTTSDALE, AZ, November 11, 2025 – CND Life Sciences, Inc. (CND), a medical technology company…
News Release
November 6, 2025

Using Skin Biopsy Technology, CND Life Sciences Performs the 50,000th Syn-One Test® for Patients

CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Skin Biopsy Test Kit

Our suite of neurodiagnostic tests provides clinicians with objective pathological insights on diseases that are often difficult to diagnose. Using our Skin Biopsy Test Kit, collect three small skin biopsies from your patient, send them to our CLIA-certified and CAP-accredited lab, and CND will provide important pathological insights to support a diagnosis.

Order a Kit